Clinical Trial of Upfront Haploidentical or Unrelated Donor BMT to Restore Normal Hematopoiesis in Aplastic Anemia (NCT06517641)

🧪 Interventions in This Study

• Haploidentical donor bone marrow transplant (DRUG)
• Unrelated donor bone marrow transplant (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (25 Sites)

• University of Alabama at Birmingham — Birmingham, Alabama
• City of Hope — Duarte, California
• University of California, Los Angeles — Los Angeles, California
• Stanford University — Stanford, California
• Moffitt Cancer Center — Tampa, Florida
• Emory Winship Cancer Institute — Atlanta, Georgia
• Blood and Marrow Transplant Center at Northside Hospital — Atlanta, Georgia
• University of Kansas Medical Center — Westwood, Kansas
• Johns Hopkins University — Baltimore, Maryland
• Massachusetts General Hospital — Boston, Massachusetts
• Dana Farber Cancer Institute — Boston, Massachusetts
• Karmanos Cancer Institute — Detroit, Michigan
• Mayo Clinic — Rochester, Minnesota
• Washington University School of Medicine, Barnes-Jewish Hospital — St Louis, Missouri
• Memorial Sloan Kettering Cancer Center — New York, New York
• UNC Chapel Hill — Chapel Hill, North Carolina
• Levine Cancer Institute — Charlotte, North Carolina
• Duke University Health System — Durham, North Carolina
• The Ohio State University — Columbus, Ohio
• University of Oklahoma — Oklahoma City, Oklahoma
• University of Pennsylvania — Philadelphia, Pennsylvania
• Vanderbilt University — Nashville, Tennessee
• Huntsman Cancer Institute — Salt Lake City, Utah
• Fred Hutchinson Cancer Center — Seattle, Washington
• Medical College of Wisconsin — Milwaukee, Wisconsin

📞 Contact the Study Coordinator

Phone: (301) 251-1161

Email: bmtctn2207@emmes.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Severe Aplastic Anemia

• A Trial Comparing Unrelated Donor BMT With IST for Pediatric and Young Adult Patients With Severe Aplastic Anemia (TransIT, BMT CTN 2202) — Birmingham, Alabama
• Sirolimus (Rapamune ) for Relapse Prevention in People With Severe Aplastic Anemia Responsive to Immunosuppressive Therapy — Bethesda, Maryland
• JAK1/2 Inhibitor Ruxolitinib for Relapsed/Refractory Immune Bone Marrow Failure — Bethesda, Maryland
• Eltrombopag With Standard Immunosuppression for Severe Aplastic Anemia — Bethesda, Maryland
• Haploidentical Bone Marrow Transplant With Post-Transplant Cyclophosphamide for Patients With Severe Aplastic Anemia — Atlanta, Georgia
• Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome — Bethesda, Maryland

Explore by condition: All Severe Aplastic Anemia clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.